Drugs / 68Ga-DOTATATE

Trials 25

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 06 trials
Phase 0 NCT05069220 Sep 2021 → Sep 2025 overdue neuroblastoma, paraganglioma, pheochromocytoma Peking Union Medical College Hospital Recruiting No outcome recorded
Phase 0 NCT04040088 Sep 2019 → Jul 2026 overdue ganglioneuroblastoma, ganglioneuroma, neuroblastoma Mayo Clinic Active not recruiting No outcome recorded
Phase 0 NCT03623984 Jun 2019 → Jun 2022 carcinoid tumor, pancreatic endocrine carcinoma University of Alabama at Birmingham Withdrawn No outcome recorded
Phase 0 NCT04041882 Apr 2014 → Dec 2020 neuroendocrine neoplasm Peking Union Medical College Hospital Unknown No outcome recorded
Phase 0 NCT01873248 Aug 2013 → Jun 2017 neuroendocrine neoplasm Jonsson Comprehensive Cancer Center Completed No outcome recorded
Phase 0 NCT01524016 Dec 2011 → Dec 2017 Oncogenic osteomalacia, mesenchymal cell neoplasm Peking Union Medical College Hospital Unknown No outcome recorded
Phase 12 trials
Phase 1 NCT06520319 Jun 2023 → Dec 2024 overdue medullary thyroid gland carcinoma First Affiliated Hospital of Fujian Medical University Recruiting No outcome recorded
Phase 1 NCT04689893 Mar 2020 → Mar 2021 Oncogenic osteomalacia Peking Union Medical College Hospital Unknown No outcome recorded
Phase 1/25 trials
Phase 1/2 NCT05990998 Nov 2022 → Aug 2023 — First Affiliated Hospital of Fujian Medical University Completed No outcome recorded
Phase 1/2 NCT03736564 Jan 2019 → Oct 2023 osteomalacia Mayo Clinic Completed No outcome recorded
Phase 1/2 NCT03648073 Jan 2019 → Feb 2022 hepatocellular carcinoma University of Alabama at Birmingham Completed No outcome recorded
Phase 1/2 NCT02078843 Mar 2014 → Aug 2016 digestive system neuroendocrine neoplasm Insel Gruppe AG, University Hospital Bern Terminated No outcome recorded
Phase 1/2 NCT02038738 Mar 2014 → Mar 2019 adenoma, carcinoid tumor, neuroendocrine carcinoma, neuroendocrine disorder +1 Ochsner Health System Unknown No outcome recorded
Phase 26 trials
Phase 2 NCT07284589 Dec 2025 → Apr 2030 expected neuroendocrine neoplasm Akiva Mintz Recruiting No outcome recorded
Phase 2 NCT05880394 Jan 2023 → Jul 2024 breast cancer Hoag Memorial Hospital Presbyterian Unknown No outcome recorded
Phase 2 NCT04559217 Dec 2021 → Dec 2027 expected neuroblastoma Centre de recherche du Centre hospitalier universitaire de Sherbrooke Recruiting No outcome recorded
Phase 2 NCT03448458 Feb 2018 → Feb 2023 castration-resistant prostate carcinoma, metastatic prostate carcinoma Emory University Completed No outcome recorded
Phase 2 NCT02019706 Feb 2014 → Dec 2030 expected ectopic Cushing syndrome National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Recruiting No outcome recorded
Phase 2 NCT00001277 Dec 1993 → Mar 2020 hypercalcemia disease, multiple endocrine neoplasia type 1 National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Completed No outcome recorded
Phase 31 trial
Phase 3 NCT04043377 Nov 2019 → Sep 2021 coronary atherosclerosis Assistance Publique - Hôpitaux de Paris Terminated No outcome recorded Stop: Business
Phase 41 trial
Phase 4 NCT03549598 Jul 2018 → Oct 2019 cardiac sarcoidosis Mayo Clinic Completed No outcome recorded
Phase not applicable2 trials
— NCT02546388 Oct 2015 → Aug 2018 cardiac sarcoidosis Marcelo F. Di Carli, MD, FACC Completed No outcome recorded
— NCT01879657 Mar 2013 → Dec 2015 neuroendocrine carcinoma Radio Isotope Therapy of America Completed No outcome recorded
Phase not stated2 trials
— NCT02174679 — carcinoid tumor, medullary thyroid gland carcinoma Jonsson Comprehensive Cancer Center No longer available No outcome recorded
— NCT01980732 — carcinoid tumor, pancreatic neuroendocrine tumor Andrei Iagaru No longer available No outcome recorded

Evidence & citations 8 cited values

Every value below carries the sentence it was read from. 25 sources stand behind the page.

FieldValueCited text
Known as 68Ga-DOTATATE “Each patient received a single intravenous injection of 68Ga-DOTATATE (2-4 mCi) and underwent PET/CT scanning 40-60 minutes after the injection.” NCT06520319 ↗
19

“Participants will be injected with 68Ga-DOTATATE and imaged for up to 3 hours on a PET scanner” NCT07284589 ↗

“Subjects will undergo imaging by 68Ga-DOTATATE PET/CT” NCT03736564 ↗

NCT04041882 ↗

NCT02038738 ↗

NCT07284589 ↗

NCT01879657 ↗

NCT05069220 ↗

NCT00001277 ↗

NCT03549598 ↗

NCT05990998 ↗

Show 9 more sources

Known as Gallium Dotatate ClinicalTrials.gov intervention name — accepted as the source's own label NCT03623984 ↗
Known as Gallium Ga 68-DOTATATE ClinicalTrials.gov intervention name — accepted as the source's own label NCT04040088 ↗
1

NCT03448458 ↗

Known as Gallium-68 (68Ga)-Dotatate “The radiotracer, Gallium-68 (68Ga)-Dotatate, is FDA-approved for detecting neuroendocrine cancer at standard doses.” NCT07284589 ↗
Known as Gallium-68 DOTATATE “Gallium-68 Dotatate, a radioactive imaging agent, is injected into a vein.” NCT03736564 ↗
3

NCT05880394 ↗

NCT02546388 ↗

NCT02078843 ↗

Modality Diagnostic / imaging agent “Patients scanned using imaging agents 68GALLIUM-DOTATATE and 18F-DOPA” NCT00001277 ↗
Route Intravenous “Intravenous injection of one dosage of 72-185MBq (2-5 mCi) 68Ga-DOTATATE solution” NCT01524016 ↗
Target SSTR2 “high affinity and selectivity for somatostatin receptor 2 (SSTR 2)” NCT04043377 ↗